Results 231 to 240 of about 833,484 (332)

Brd4 BD1 Domain Antagonism of MS436 Preserves Blood‐Brain Barrier Integrity via Rnf43/β‐Catenin Signaling Pathway

open access: yesAdvanced Science, EarlyView.
MS436 competitively binds to the BD1 domain of Brd4, thereby suppressing Brd4 induced degradation of tight junction proteins via the Rnf43‐Fzd4‐β‐catenin signaling pathway. Consequently, this attenuation of degradation reduces blood‐brain barrier leakage, leading to an improved overall prognosis after stroke.
Chenxiao Li   +10 more
wiley   +1 more source

Endothelial Cell‐Specific Molecule‐1 (ESM1): An Endogenous Anticoagulant and Protective Factor in Venous Thrombosis

open access: yesAdvanced Science, EarlyView.
This study identifies ESM1 as an endogenous anticoagulant that modulates venous thrombosis. It shows that ESM1 deficiency triggers vascular occlusion in zebrafish and mice, whereas its restoration or overexpression prolongs clot‐formation time. Mechanistic analyses reveal that ESM1 activates HCII through its dermatan‐sulfate chain, uncovering a ...
Changsheng Chen   +10 more
wiley   +1 more source

Study on the Effect of Different Occlusal Schemes on Temporomandibular Joint Health in Complete Denture Wearers.

open access: yesJ Pharm Bioallied Sci
Sinha RR   +5 more
europepmc   +1 more source

A Novel and Simple Score to Predict Embolic or Atherosclerotic Middle Cerebral Artery Occlusion Before Mechanical Thrombectomy: AHOC Score. [PDF]

open access: yesCNS Neurosci Ther
Zhang H   +17 more
europepmc   +1 more source

Combined cilioretinal artery and hemi-retinal vein occlusion in Sturge Weber syndrome: Expanding the clinical spectrum

open access: hybrid, 2017
Sawsan S. Bakri   +3 more
openalex   +1 more source

Neuroprotective Nanoplatform Integrating Antioxidant MXene Nanozymes and Ferroptosis Inhibitors for Targeted Therapy of Cerebral Ischemia‐Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
Cerebral ischemia‐reperfusion injury (CIRI) is a key pathological process limiting the efficacy of stroke therapy. This study has developed an innovative, multifunctional, brain‐targeted nanoplatform (RFP) containing MXene nanoenzymes and ferroptosis inhibitors.
Lu Wang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy